9,475 Incyte Corporation $INCY Shares Purchased by Ritholtz Wealth Management

Ritholtz Wealth Management grew its holdings in shares of Incyte Corporation (NASDAQ:INCY – Free Report) by 97.5% in the third quarter, according to its most recent filing with the SEC. The firm owned 19,195 shares of the biopharmaceutical company’s stock after acquiring an additional 9,475 shares during the quarter. Ritholtz Wealth Management’s holdings in Incyte were worth $2,329,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently modified their holdings of the company. Greenleaf Trust increased its holdings in shares of Incyte by 2.8% during the second quarter. Greenleaf Trust now owns 3,358 shares of the biopharmaceutical company’s stock valued at $381,000 after purchasing an additional 93 shares during the period. Parallel Advisors LLC lifted its holdings in Incyte by 2.4% in the third quarter. Parallel Advisors LLC now owns 5,082 shares of the biopharmaceutical company’s stock worth $617,000 after purchasing an additional 121 shares during the period. Mather Group LLC. grew its position in Incyte by 13.5% in the 3rd quarter. Mather Group LLC. now owns 1,157 shares of the biopharmaceutical company’s stock valued at $140,000 after buying an additional 138 shares in the last quarter. Tema ETFs LLC grew its position in Incyte by 5.7% in the 2nd quarter. Tema ETFs LLC now owns 2,704 shares of the biopharmaceutical company’s stock valued at $307,000 after buying an additional 145 shares in the last quarter. Finally, Trust Point Inc. grew its position in Incyte by 5.5% in the 2nd quarter. Trust Point Inc. now owns 2,968 shares of the biopharmaceutical company’s stock valued at $336,000 after buying an additional 156 shares in the last quarter. Institutional investors own 96.97% of the company’s stock.

Insider Buying and Selling

In other Incyte news, insider Thomas Tray sold 610 shares of the company’s stock in a transaction dated Tuesday, November 3rd. The shares were sold at an average price of $118.96, for a total transaction of $72,565.60. Following the completion of the sale, the insider directly owned 21,126 shares of the company’s stock, valued at approximately $2,513,148.96. This represents a 2.81% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Pablo J. Cagnoni sold 10,801 shares of the firm’s stock in a transaction that occurred on Wednesday, August 19th. The stock was sold at an average price of $125.56, for a total transaction of $1,356,173.56. Following the completion of the transaction, the insider directly owned 183,200 shares of the company’s stock, valued at $23,002,592. This represents a 5.57% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 254,246 shares of company stock worth $30,162,968 in the last three months. 16.20% of the stock is currently owned by insiders.

Incyte Stock Performance

Shares of NASDAQ INCY traded down $0.73 during trading on Friday, hitting $120.97. The company had a trading volume of 950,394 shares, compared to its average volume of 1,785,896. The company has a market cap of $24.66 billion, a P/E ratio of 64.35, a PEG ratio of 4.43 and a beta of 0.78. Incyte Corporation has a 52 week low of $89.25 and a 52 week high of $132.60. The business’s 50-day moving average is $119.18 and its 200 day moving average is $108.96.

Incyte (NASDAQ:INCY – Get Free Report) last announced its quarterly earnings data on Thursday, October 29th. The biopharmaceutical company reported ($3.60) EPS for the quarter, beating analysts’ consensus estimates of ($3.93) by $0.33. The company had revenue of $1.56 billion during the quarter, compared to the consensus estimate of $1.46 billion. Incyte had a return on equity of 7.92% and a net margin of 6.71%. The company’s quarterly revenue was up 14.0% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $2.26 EPS. On average, research analysts expect that Incyte Corporation will post 2.24 EPS for the current year.

Wall Street Analyst Weigh In

Several equities analysts have commented on the stock. Leerink Partners lowered their target price on shares of Incyte from $154.00 to $150.00 and set an “outperform” rating on the stock in a research note on Thursday, November 5th. Oppenheimer set a $152.00 price target on shares of Incyte in a research note on Tuesday, October 27th. Barclays increased their price objective on shares of Incyte from $139.00 to $143.00 and gave the company an “overweight” rating in a report on Friday, October 30th. Zacks Research upgraded shares of Incyte from a “strong sell” rating to a “hold” rating in a research note on Thursday. Finally, HC Wainwright reiterated a “buy” rating on shares of Incyte in a research note on Tuesday, October 27th. Eleven analysts have rated the stock with a Buy rating and fourteen have issued a Hold rating to the stock. Based on data from MarketBeat.com, Incyte presently has a consensus rating of “Hold” and an average target price of $132.86.

Get Our Latest Stock Report on INCY

About Incyte

(Free Report)

Incyte is a biopharmaceutical company that discovers, develops and commercializes medicines, with a focus on oncology, hematology and inflammatory and autoimmune diseases. Founded in 1991, the company is headquartered in Wilmington, Delaware, and conducts research and commercial activities in the United States and internationally. Its products include Jakafi (ruxolitinib), used to treat certain blood disorders and graft-versus-host disease, and Opzelura (ruxolitinib cream), approved in the United States for certain skin conditions.

See Also

Want to see what other hedge funds are holding INCY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Incyte Corporation (NASDAQ:INCY – Free Report).

Institutional Ownership by Quarter for Incyte (NASDAQ:INCY)

Receive News & Ratings for Incyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Incyte and related companies with MarketBeat.com's FREE daily email newsletter.